Ignite Creation Date:
2024-05-05 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 9:54 AM
Study NCT ID:
NCT00747825
Status:
TERMINATED
Last Update Posted:
2011-10-12
First Post:
2008-09-04
Brief Title:
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
Sponsor:
Molecular Insight Pharmaceuticals Inc
Organization:
Molecular Insight Pharmaceuticals Inc
Study Overview
Official Title:
A Phase I Study Evaluating the Safety Pharmacokinetics Tissue Distribution and Determination of Radiation Dosimetry for 131-I-MIP-1145
Status:
TERMINATED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label single dose study for patients 18 years of age or older with confirmed metastatic melanoma Up to 12 patients will be enrolled and all will receive an injection of approximately 40 to 60 mCi 148-222 MBq of 131-I-MIP-1145 administered via IV injection The study will consist of a single dosing day followed by a 7-day assessment period and 21-day follow-up period The total duration of the study from screening to final follow-up visit is approximately 60 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None